Zenas BioPharma's Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus [Yahoo! Finance]
Zenas BioPharma’s Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus
Zenas Prepares For INDIGO Phase 3 Readout - Reinstating Buy Rating [Seeking Alpha]
Top SA Quant rated small-cap stocks as Russell 2000 notches a record close [Seeking Alpha]
Zenas BioPharma (NASDAQ:ZBIO) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $55.00 price target on the stock.